PFIZER INC (PFE)       49.71  -1.02 (-2.01%)

49.71  -1.02 (-2.01%)

US7170811035 - Common Stock - After market: 49.65 -0.06 (-0.12%)

PFIZER INC49.71

NYSE:PFE (12/6/2022, 7:04:00 PM)-1.02 (-2.01%)

After market: 49.65 -0.06 (-0.12%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Pharmaceuticals
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-01 2022-11-01/bmo Earnings (Next) 02-06 2023-02-06
Ins Owners 0.04% Inst Owners 69.24%
Market Cap 279.04B Shares 5.61B
PE 7.57 Fwd PE 9.43
Dividend Yield 3.25% Analysts 75
IPO 01-17 1944-01-17

Stock Screener Links

Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PFE Daily chart

Company Profile

Pfizer Inc. is a research-based global biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 79,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The firm operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. The company also offers Rimegepant and Zavegepant.

Company Info

PFIZER INC

235 E 42nd St

New York City NEW YORK 10017

P: 12125732323.0

CEO: Albert Bourla

Employees: 79000

Website: https://www.pfizer.com/

PFE News

News Image13 hours ago - ReutersGSK, Pfizer, Sanofi escape U.S. federal litigation over Zantac

Drugmakers GSK Plc , Pfizer Inc , Sanofi SA and Boehringer Ingelheim on Tuesday defeated thousands of lawsuits in U.S. federal court claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science.

News Image13 hours ago - Yahoo FinanceUPDATE 1-GSK, Pfizer, Sanofi escape U.S. federal litigation over Zantac

Drugmakers GSK Plc, Pfizer Inc , Sanofi SA and Boehringer Ingelheim on Tuesday defeated thousands of lawsuits in U.S. federal court claiming that the heartburn drug Zantac caused cancer, as a judge found the claims were not backed by sound science. While the companies, which have all marketed the drug at different times, still face tens of thousands of similar lawsuits in state courts, the ruling by U.S. District Judge Robin Rosenberg in West Palm Beach, Florida, knocks out a significant portion of their potential liability. "We are extremely surprised by this miscarriage of justice and fully expect that the Eleventh Circuit Court of Appeal will reverse these rulings on appeal," lawyers for the plaintiffs said in a joint statement.

News Image13 hours ago - BloombergZantac Litigation Tossed by US Judge After Ruling on Experts

GSK Plc, Sanofi and Pfizer Inc. don’t have to face nearly 2,000 lawsuits by former users of the Zantac heart-burn treatment after a judge threw out the cases after finding the science underlying their cancer claims was invalid.

News Image14 hours ago - Seeking AlphaEU regulator says adapted COVID shots could be used for initial vaccination (NYSE:PFE)

The EU regulator said Tuesday that mRNA-based COVID-19 vaccines, targeting original strain and Omicron BA.4/ BA.5 subvariants, may be used for initial vaccinations. Read full story here.

News Image15 hours ago - SBWireNanomedicine Market Size & Share Report 2022 : Reach at US$ 238.4 Bn and Grow at Healthy CAGR 10.1% During Forecast Period 2022-2028

"Emerging innovative technologies for drug delivery, the benefits of nanomedicine in various healthcare applications, and the increase in the demand for safe and inexpensive treatments drive the growth of the nanomedicine market."

News Image16 hours ago - CNBCPfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history

Pfizer asked a federal court in Boston on Monday to dismiss Moderna's lawsuit seeking monetary damages for alleged patent violations related to the Covid vaccine.

PFE Twits

Here you can normally see the latest stock twits on PFE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example